fda warning letters compounded semaglutide tirzepatide september 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA unleashes warning letters to

New England Journal of Medicine 37518341844

PlexusDx serves all 50 states with no insurance requirement, no membership fees, and direct pricing starting at $149 per month for Semaglutide Injection

The typical insulin-lowering effect in T1D is often modest, commonly cited around 5% in practice summaries

(NYSE: PFE) announced positive topline results from the phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes

[DOI] [PubMed] [Google Scholar] 72.Sumida Y., Yoneda M., Tokushige K., Kawanaka M., Fujii H., Yoneda M., Imajo K., Takahashi H., Eguchi Y., Ono M., et al

After stopping tirzepatide, increased blood glucose monitoring is recommended for at least 2-4 weeks